



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>4</sup> :  <b>C07K 15/00, C07H 17/02</b>  <b>C12N 15/00</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 89/0979</b></p> <p>(43) International Publication Date: 19 October 1989 (19.10.8)</p>	
<p>(21) International Application Number: PCT/US89/01548</p> <p>(22) International Filing Date: 13 April 1989 (13.04.89)</p> <p>(30) Priority data:  182,646 14 April 1988 (14.04.88) US</p> <p>(71) Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; Chapel Hill, NC 27599 (US).</p> <p>(72) Inventors: FRENCH, Frank, S. ; 503 Dogwood Drive, Chapel Hill, NC 27514 (US). WILSON, Elisabeth, M. ; 913 Emory Drive, Chapel Hill, NC 27514 (US). JOSEPH, David, R. ; 115 Lexington Road, Chapel Hill, NC 27514 (US). LUBAHN, Dennis, B. ; 1720 Euclid Road, Durham, NC 27713 (US).</p>		<p>(74) Agents: HUNTER, Marjorie, D. et al.; One Baxter Parkway, Deerfield, IL 60015 (US).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p><b>Published</b>  <i>With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	


**(54) Title:** DNA ENCODING ANDROGEN RECEPTOR PROTEIN

**(57) Abstract**

**DNA sequences encoding human androgen receptor protein and polypeptides and proteins having substantially the same biological activity as human androgen receptor protein and the amino acid sequences of human androgen receptor protein and polypeptides and proteins having substantially the same biological activity as human androgen receptor protein are disclosed. Methods for the production and use of such compositions are also disclosed.**

Oligo A	Complement	5'-ACC GG	TGT GGG	GAG G	GCC G	TGT GG	AAG GGG	UTC GGG	TTC GGG	TTC GGG	AAA GGG	AG-3' (100%)
BAR (2)		ACA	TGT	GCA	AGC	TGC	AAC	GTC	TTC	TTC	AAA	AG (84%)
BPR (11)		ACC	TGT	GCC	AGC	TGT	AAC	GTC	TTC	TTT	AAC	AG (83%)
BWR (4)		ACC	TGT	GCC	AGC	TGC	AAA	GTT	TTC	TTC	AAA	AG (81%)
BGR (3)		ACT	TGT	GCA	AGC	TGT	AAA	TTT	TTC	TTC	AAA	AG (81%)
BXR (6)		TCG	TGT	GAG	GCC	TGT	AAC	GCC	TTC	TTC	AAC	AG (91%)
BZJR (3, 17)		ATC	TGT	GAA	GCC	TGC	AAC	GCT	TTC	TTT	ACA	AG (78%)
BRAR (17)		CCC	TGT	GAG	GCC	TGC	AAC	GCC	TTC	TTC	CCC	CG (78%)

3.



c.

### DNA-Binding Domain

[illegible][illegible]

**FOR THE PURPOSES OF INFORMATION ONLY**

AC	Austria	GA	Gabon	ML	Mali
BB	Barbados	GB	United Kingdom	MR	Mauritania
BE	Belgium	HU	Hungary	MW	Malawi
BG	Bulgaria	IT	Italy	NL	Netherlands
BJ	Benin	JP	Japan	NO	Norway
BR	Brazil	KP	Democrat	RO	Romania
CF	Central A		of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany, Federal Republic of	LU	Luxembourg	TD	Chad
DK	Denmark	MC	Monaco	TG	Togo
FI	Finland	MG	Madagascar	US	United States of America

## DNA ENCODING ANDROGEN RECEPTOR PROTEIN

5           This invention was made in the course of research supported in part by grants from the National Institutes of Health (NIH HD 16910, HD 04466, and HD 18968).

### TECHNICAL FIELD OF THE INVENTION

10           This invention relates to recombinant DNA molecules and their expression products. More specifically this invention relates to recombinant DNA molecules coding for androgen receptor protein, androgen receptor protein, and use of the DNA molecules and protein in investigatory, diagnostic and therapeutic applications.

15

### BACKGROUND OF THE INVENTION

          The naturally occurring androgenic hormones, testosterone and its 5 -reduced metabolite, dihydrotestosterone, are synthesized by the Leydig cells of the testes and circulate throughout the body  
20       where they diffuse into cells and bind to the androgen receptor protein ("AR"). Androgens, acting through their receptor, stimulate development of the male genitalia and accessory sex glands in the fetus, virilization and growth in the pubertal male, and maintenance of male virility and reproductive function in the adult. The  
25       androgen receptor, together with other steroid hormone receptors constitute a family of trans-acting transcriptional regulatory proteins that control gene transcription through interactions with specific gene sequences.

          When prostate cancer is found to be confined to the prostate

          diagnosis. Most of their tumors (70 to 80%) respond to the removal of androgen by castration or by suppression of luteinizing hormone secretion by the pituitary gland.

- 2 -

releasing hormone analogue alone or in combination with an anti-androgen. The degree and duration of response to this treatment is highly variable (10% live < 6 months, 50% live < 3 years, and 10% live > 10 years.) Initially cancer cells regress  
5 without androgen stimulation, but ultimately the growth of androgen independent tumor cells continues (35). At present it is not possible to predict on an individual basis which patient will respond to hormonal therapy and for how long. If poorly responsive patients could be identified early, they could be treated by  
10 alternative forms of therapy (e.g. chemotherapy) at an earlier stage when they might be more likely to respond.

Studies on androgen receptors in prostate cancer have suggested that a positive correlation may exist between the presence of androgen receptors in cancer cells and their dependence on  
15 androgenic hormone stimulation for growth. (An analogous situation exists in mammary carcinoma where there is a correlation between estrogen receptors and regression of the tumor in response to estrogen withdrawal). However, methodological problems in the measurement of androgen receptors have prevented the routine use of  
20 androgen receptor assays in the diagnostic evaluation of prostate cancer. Prior to our preparation of androgen receptor antibodies, all androgen receptor assays were based on the binding of [<sup>3</sup>H]-labeled androgen. These assays have been unreliable in human prostate cancer tissue because of the extreme lability of the  
25 androgen binding site and the presence of unlabeled androgen in the tissue. Endogenous androgen occupies the binding site on the receptor and dissociates very slowly (t 1/2 24-48 hr at 0C). A further problem is that biopsy samples are quite small, making it

be an uneven distribution of cells containing androgen receptors.

Development of the male phenotype and maturation of male

- 3 -

hormones with the androgen receptor protein and the subsequent function of the receptor as a trans-acting inducer of gene expression. It has become well established over the past twenty-five years that genetic defects of the androgen receptor result in a broad spectrum of developmental and functional abnormalities ranging from genetic males (46,XY) with female phenotype to phenotypically normal males with infertility. Isolation of the structural gene for the androgen receptor makes it possible to define the nature of these genomic defects in molecular terms. Analysis of the functional correlates of the genetic defects may lead to a better understanding of the regulation of androgen receptor gene expression and of the mechanism of androgen action in male sexual development and function.

The androgen insensitivity syndrome, known also as testicular feminization, is characterized by an inability to respond to androgen due to a defect in the androgen receptor, the protein that mediates the action of androgen within the cell. Androgen insensitivity is an inherited X-linked trait that occurs in both complete and incomplete forms. The complete form results in failure of male sex differentiation during embryogenesis and absence of virilization at puberty. The result is a 46,XY genetic male with testes and male internal ducts. The testes produce normal amounts of testosterone and Mullerian inhibiting substance. Consequently development of the uterus is inhibited as in the normal male. Because of the inability to respond to androgen, the external genitalia remain in the female phenotype with normal clitoris and labia. A small vagina develops from the urogenital sinus and ends in a blind pouch. At puberty feminization with breast development and female contours occur in response to testicular estrogen,

a normal male.

Incomplete forms of the androgen insensitivity syndrome include a spectrum of phenotypes resulting from varying degrees of

- 4 -

incomplete androgen responsiveness. At one extreme, individuals have mild enlargement of the clitoris and sparse pubic hair. The opposite extreme is characterized by more complete masculinization with varying degrees of hypospadias deformity but predominantly a male phenotype. It has been reported that some adult men with severe oligospermia or azoospermia who are otherwise normal, have defects in the androgen receptor. These may include as many as 10% of infertile males.

The genetic defect eliciting this range of abnormalities is thought to be a single biochemical event at the level of the gene for the androgen receptor. The androgen receptor is a high affinity androgen binding protein that mediates the effects of testosterone and dihydrotestosterone by functioning as a trans-acting inducer of gene expression. For proper male sexual development to occur, there is a requirement for androgen and its receptor at a critical time during embryogenesis and during puberty. The majority of individuals with the androgen insensitivity syndrome have a history of affected family members, although about a third are thought to represent new mutations of this X-linked disorder. The incidence ranges from 1 in 20,000 to 60,000 male births.

In studies of families with clinical evidence of the androgen insensitivity syndrome, four main categories were recognized that range from the most severe, complete absence of receptor binding activity in a genetic male with female phenotype, to qualitatively normal receptor in affected individuals. Second in severity are affected individuals with qualitatively abnormal androgen binding by receptor present in normal levels. Examples include the failure of sodium molybdate (a reagent often used in studies on steroid

receptor under conditions that cause transformation had also been reported. A third group expresses a decreased amount of receptor with wild-type in vitro binding characteristics. The final

- 5 -

whom no abnormality in receptor is detected. In a recent study of this form of the syndrome, the androgen receptor was as capable of binding oligonucleotides as the wild-type receptor. Indeed, with the techniques available until only recently, it has been difficult  
5 in certain cases to document an androgen receptor defect in affected individuals.

Experimental methods used in assessing receptor defects in the past have relied on the ability of receptor to bind androgen with high affinity. The limitation of this methodology is that it is not  
10 possible to distinguish between the lack of expression of the receptor and loss of androgen binding activity. An example of how inadequate methodology complicates diagnosis is the absence of detectable receptor binding activity in patients who are partially virilized. It is theoretically possible for a mutation to occur  
15 which allows the receptor with defective androgen binding activity to induce gene transcription. Biologically active truncated forms of the glucocorticoid receptor that lack steroid binding activity but retain the DNA binding domain have been demonstrated using genetically engineered mutants.

20 Purification of the androgen receptor has been difficult to accomplish due to its low concentration and high degree of instability. Reported attempts at purification using either conventional methods of column chromatography or steroid-affinity chromatography have yielded insufficient amounts of receptor protein  
25 to allow even the preparation of monoclonal antibodies.

An early report on the partial purification of the androgen receptor was disclosed by Mainwaring et al. in "The use of DNA - cellulose chromatography and isoelectric focusing for the characterization and partial purification of steroid-receptor

at ventral prostate and determined its physicochemical properties. This group was among the first to attempt the use of steroid affinity chromatography in conjunction with conventional

- 6 -

chromatography, using the affinity label  
17B-bromoacetoxytestosterone in receptor purification (See  
Mainwaring et al., "Use of the affinity label  
17B-bromoacetoxytestosterone in the purification of androgen  
5 receptor proteins," Perspectives in Steroid Receptor Research,  
(1980)). Partial purification of androgen receptor has also been  
attempted from other tissue sources, such as ram seminal vesicles  
(See Foekens et al., Molecular Cellular Endocr, 23, 173-186 (1981)  
and Foekens et al., "Purification of the androgen receptor of sheep  
10 seminal vesicles," Biochem Biophys Res Comm, 104, 1279-1286  
(1982)). The partially purified receptor displayed characteristics  
of a proteolyzed receptor, but a purification of 2,000 fold was  
reported with a recovery of 33% (See Foekens et al., "Purification  
of the androgen receptor of sheep seminal vesicles," Biochem Biophys  
15 Res Comm, 104, 1279-1286 (1982)). Later attempts at purification  
continued to combine steroid affinity chromatography with  
conventional techniques, reportedly achieving significant  
purification, but recoveries too low for further analysis (See Chang  
et al., "Purification and characterization of androgen receptor from  
20 steer seminal vesicle," Biochemistry 21, 4102-4109 (1982), Chang et  
al., "Purification and characterization of the androgen receptor  
from rat ventral prostate," Biochemistry 22, 6170-6175 (1983) and  
Chang et al., "Affinity labeling of the androgen receptor in rat  
prostate cytosol with  
25 17B-[(bromoacetyl)oxy]-5-alpha-androstan-3-one," Biochemistry 23,  
2527-2533 (1984)). More recent studies examine the effectiveness of  
a variety of immobilized androgens for their ability to bind the  
androgen receptor (See De Larminat et al., "Synthesis and evaluation

(1984) and Bruchovsky et al., "Chemical demonstration of nuclear  
androgen receptor following affinity chromatography with immobilized  
ligands," The Prostate 10, 207-222 (1987)). Despite these efforts



- 7 -

the quantities of purified androgen receptor obtained have been insufficient for the production of antisera.

Clinical assays for the androgen receptor now include several methods. The most common is the binding of tritium-labeled hormone and measurement of binding using a charcoal adsorption assay. Either a natural androgen, such as dihydrotestosterone, or synthetic androgen, such as mibolerone or methyltrienolone (R1881), can be used. An advantage of the latter in human tissue is that it is not significantly metabolized and does not bind to the serum androgen binding protein, sex steroid binding globulin. A limitation of radioisotope labeling of receptor is interference caused by endogenous androgen. Although exchange assays for the androgen receptor have been described (See Carroll et al., J Steroid Biochem 21, 353-359 (1984) and Traish et al., J Steroid Biochem 23, 405-413 (1985)), their effectiveness is limited by the slow kinetics of dissociation of the endogenous receptor-bound androgen.

Another method used to assess receptor status is autoradiography. In this method disclosed in Barrack et al., "Current concepts and approaches to the study of prostate cancer," Progress in Clinical and Biological Research, 239, 155-187 (1987) the radioactively labeled androgen is incubated with slide-mounted tissue sections of small tissue biopsy specimens which are then frozen, sectioned and fixed. Nuclear localization of radioactivity is detected by exposure of tissue sections to x-ray film. This technique requires considerable technical expertise, is labor intensive, and requires extended periods of exposure time. It is therefore of limited usefulness in general clinical assays. Another problem is high levels of background signal, i.e. a high noise/signal ratio, making it difficult to distinguish

WO 87/05049 (Shine) discloses a method for the production of purified steroid receptor proteins, specifically estrogen receptor proteins, through the expression of complementary DNA

- 8 -

such proteins in eukaryotic host cells. However, the reference does not disclose the sequence for androgen receptor protein, nor does it disclose a method for obtaining such a sequence.

5     SUMMARY OF THE INVENTION

          The present invention provides a DNA sequence characterized by a structural gene coding for a polypeptide having substantially the same biological activity as androgen receptor protein. A DNA sequence encoding androgen receptor protein or a protein having  
10     substantially the same biological activity as androgen receptor activity is also provided. DNA sequences may be obtained from cDNA or genomic DNA, or prepared using DNA synthesis techniques.

          The invention further discloses cloning vehicles comprising a DNA sequence comprising a structural gene encoding a polypeptide  
15     having substantially the same biological activity as androgen receptor protein. Cloning vehicles comprising a DNA sequence encoding androgen receptor protein or a protein having substantially the same biological activity as androgen receptor protein is also provided. The cloning vehicles further comprise a promoter sequence  
20     upstream of and operatively linked to the DNA sequence. In general the cloning vehicles will also contain a selectable marker, and, depending on the host cell used, may contain such elements as regulatory sequences, polyadenylation signals, enhancers and RNA splice sites.

25     The invention further provides cells transfected or transformed to produce androgen receptor protein or a protein having substantially the same biological activity as androgen receptor protein.

          substantially the same biological activity as androgen receptor activity, and methods for producing such proteins and polypeptides.

- 9 -

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a comparison of DNA-binding domains of the human androgen receptor (hAR) with members of the nuclear receptor family. (A) is a comparison of oligo A nucleotide sequence with sequences of hAR and other nuclear receptors: hPR, human progesterone receptor; hMR, human mineralocorticoid receptor; hGR, human glucocorticoid receptor; hER, human estrogen receptor; hT3R, human thyroid hormone receptor; hRAR, human retinoic acid receptor. Chromosomal locations are shown in parentheses at the left.

5 Nucleotide identity between oligo A and hAR is indicated with an asterisk. The percent homology with oligo A is in parentheses at the right of each sequence. (B) shows the structure of fibroblast clone ARHFL1 human fibroblast clone [1]). Nucleotide residues are numbered from the 5'-terminus. Restriction

10 endonuclease sites were determined by mapping or were deduced from DNA sequence. The TGA translation termination codon, determined by comparison with hPR, hMR and hGR, follows a long open reading frame containing sequences homologous to those of other steroid receptors. Arrows indicate exon boundaries in genomic clone X05AR.

15 The hatched area is the putative DNA binding domain. (C) shows a comparison of amino acid sequences of the AR DNA-binding domain with sequences of the nuclear receptor family. AR amino acid sequence was deduced from nucleotide sequence of clone ARHFL1 and is numbered beginning with the first conserved cysteine residue (+). Amino acid

20 numbers in parentheses at the left indicate the residue number of the first conserved cysteine from the references indicated above. Percent homology with hAR is indicated in parentheses on the right. The region of the DNA-binding domain from which the oligo A sequence was derived is underlined in hAR. Coding DNA of residues 1 to 31 is

Abbreviations for amino acid residues are:

- 10 -

A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

Figure 2 illustrates the steroid binding properties of expressed AR cDNA. (A) shows the structure of pCMVAR in the expression vector pCMV containing the human cytomegalovirus(CMV) promoter of the immediate early gene, poly(A) addition-transcription terminator region of the human growth hormone gene (hGH poly A), SV40 origin of replication (SV40 Ori), and a polylinker region for insertion of cDNAs. The plasmid pTEBR contains the ampicillin resistance gene (Amp). (B) shows saturation analysis of [<sup>3</sup>H]dihydrotestosterone binding in extracts of pCMVAR transfection of COS M6 cells. Portions of cytosol (0.1 ml, 0.3 mg/ml protein) were incubated overnight at 4°C with increasing concentrations of [<sup>3</sup>H]-labeled hormone and analyzed by charcoal adsorption. Nonspecific binding increased from 18% to 37% of total bound radioactivity. (C) shows a scratched plot analysis of [<sup>3</sup>H]dihydrotestosterone binding. Error estimation was based on linear regression analysis ( $r=0.966$ ). (D) illustrates the competition of unlabeled steroids for binding of 5 nM [<sup>3</sup>H]dihydrotestosterone in transfected COS M6 cell extracts. Unlabeled steroids were added at 10- and 100-fold excess of labeled hormone. Specific binding was determined as previously described.

Figure 3 is a compiled clone map of the human androgen receptor. The map shows the structure of the human androgen receptor gene and the relative positions of the nucleic acid sequences contained in the cDNA probes [A], [B], [C] and [D], human fibroblast clone [1], human epididymis clones [1] and [5], human

Figure 3 shows a compiled clone map of the human androgen receptor cDNA and the deduced amino acid sequence.

- 11 -

Figure 5 shows the complete nucleotide sequence of the rat androgen receptor cDNA and the predicted amino acid sequence.

Figure 6 is a photograph of a frozen section of rat ventral prostate stained with antibodies (AR-52-3-p) to the AR peptide  
5 NH<sub>2</sub>-Asp-His-Val-Leu-Pro-Ile-Asp-Tyr-Tyr-Phe-Pro-Pro-Gln-Lys-Thr in a dilution of 1 to 3000 using the avidin-biotin peroxidase technique. Androgen receptor is indicated by brown staining of nuclei in epithelial cells.

Figure 7 is a photograph showing restriction fragment length  
10 polymorphisms in the human androgen receptor gene.

Figure 8 is a photograph showing a Southern blot analysis in the human androgen receptor gene in complete androgen insensitivity syndrome patients.

15 DETAILED DESCRIPTION OF THE INVENTION

In the description the following terms are employed:

Nucleotide

A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate,, and a nitrogenous heterocyclic base. The  
20 base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and that combination of base and sugar is a nucleotide. The base characterizes the nucleotide. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C") and thymine ("T"). The four RNA bases are A, G, C and uracil ("U"). A and G  
25 are purines, abbreviated to R, and C, T, and U are pyrimidines, abbreviated to Y.

DNA Sequence

A linear series of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5'

- 12 -

### Codon

A DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translational start signal or a translational termination signal. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encode for the amino acid leucine ("Leu"), TAG, TAA and TGA are translational stop signals and ATG is a translational start signal.

### Reading Frame

The grouping of codon's during translation of mRNA into amino acid sequences. During translation the proper reading frame must be maintained. For example, the sequence GCTGGTTGTAAG may be translated in three reading frames or phases, each of which affords a different amino acid sequence:

GCT GGT TGT AAG - Ala-Gly-Cys-Lys  
G CTG GTT GTA AG - Leu-Val-Val  
GC TGG TTG TAA A - Trp-Leu-(STOP)

### Polypeptide

A linear series of amino acids connected one to the other by peptide bonds between the  $\alpha$ -amino and carboxy groups of adjacent amino acids.

### Genome

The entire DNA of a substance. It includes inter alia the structural genes encoding for the polypeptides of the substance, as well as operator, promoter and ribosome binding and interaction sequences including sequences such as the Shine-Dalgarno sequences.

### Structural Gene

A DNA sequence which encodes through its template or messenger RNA ("mRNA") a sequence of amino acids characteristic of a specific polypeptide.

### Translation

The process of producing a polypeptide from mRNA.

- 13 -

### Expression

The process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation.

### Plasmid

5 A non-chromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism are changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying  
10 the gene for tetracycline resistance ( $Tet^R$ ) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called a "transformant".

### Phage or Bacteriophage

Bacterial virus many of which include DNA sequences  
15 encapsidated in a protein envelope or coat ("capsid"). In a unicellular organism a phage may be introduced as free DNA by a process called transfection.

### Cloning Vehicle

A plasmid, phage DNA or other DNA sequences which are able to  
20 replicate in a host cell, characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which  
25 contain a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector.

### Cloning

The selection and propagation of a single species.

sequences... nature with the second.

- 14 -

## Expression Control Sequence

A DNA sequence of nucleotides that controls and regulates expression of structural genes when operatively linked to those genes.

5 To attain the objects of this invention it was necessary to determine the amino acid sequence and the DNA sequence of the structural gene encoding androgen receptor protein. One conventional approach would involve starting with the purified androgen receptor protein. However, as described above, significant  
10 amounts of the protein for such purposes have not been obtained.

An alternative approach to circumvent the overwhelming difficulty of androgen receptor protein purification is direct isolation of the DNA encoding the messenger RNA for androgen receptor protein.

15 Our strategy for isolating AR DNA was based on evidence that the AR gene is X-linked and that no other steroid receptor gene is located on the X chromosome. Sequence data are available from cDNAs for glucocorticoid, estrogen, progesterone, mineralocorticoid and vitamin D receptors. Comparison of the derived amino acid sequences  
20 has revealed a central region of high cysteine content which was found also in the v-erb A oncogene product recently identified as the thyroid hormone receptor. Within this 61-63 amino acid region is an arrangement of 9 cysteine residues that are absolutely conserved among steroid receptors thus far characterized. The  
25 overall homology among sequences in this conserved region ranges between 40 and 90%. We assumed that AR would resemble other members of the steroid receptor family in the conserved DNA-binding domain.

A human X chromosomal library was screened with the synthetic

consensus sequence from the conserved sequence of the DNA-binding domain of other steroid receptors. Screening the library with the oligo A probe resulted in several recombinants whose inserts were



- 15 -

clone (Charon 35 X05AR) (human genomic clone [1]) contained a sequence similar to, yet distinct from, the DNA-binding domains of other steroid receptors. It had 84% sequence identity with oligo A, while other receptor DNAs were 78% to 91% homologous with the  
5 consensus oligonucleotide.

From the nucleotide sequence just 5' of the DNA binding domain, oligonucleotide probe B (Oligo B sequence = <sup>5</sup>GGA CCA TGT TTT GCC CAT TGA CTA TTA CTT TCC ACC CC<sup>3'</sup>) was synthesized and used to screen bacteriophage lambda gt11 cDNA libraries from human  
10 epididymis and cultured human foreskin fibroblasts. Recombinant phage (unamplified) screened with this oligonucleotide by in situ hybridization revealed one positive clone in each library. The epididymal clone (gt11 ARHEL1)(human epididymis clone [1]) contained the complete DNA-binding domain and approximately 1.5 kb of upstream  
15 sequence, whereas the fibroblast clone (gt11 ARHFL1)(human fibroblast clone [1]) shown in Figure 1(B) contained the DNA-binding domain and 1.5 kb of downstream sequence. The DNA-binding domains of the cDNA isolates were identical to that of the genomic exon sequence.

20 Transient expression in monkey kidney cells (COS M6) demonstrated that the human foreskin fibroblast cDNA fragment encodes the steroid-binding domain of hAR. A DNA fragment (ARHFLIH-X) extending 5' to 3' from the Hind III site within the putative DNA-binding domain through the stop codon (TGA) was cloned  
25 into pCMV as shown in Figure 2(A). Expression was facilitated by adding to the 5' end a consensus translation initiation sequence containing the methionine codon (ATG) in reading frame. Transfection of the recombinant construct produced a protein with

that of native AR. The level of expressed protein, 1.3 pmol per milligram of protein, was 20 to 60 times greater than that in male

- 16 -

transfections with plasmid DNA lacking the AR insert yielded no specific binding of dihydrotestosterone. Figure 2(D) shows steroid specificity was identical to that of native AR, with highest affinity for dihydrotestosterone and testosterone, intermediate  
5 affinity for progesterone and estradiol, and low affinity for cortisol.

Figure 3 is a clone map compiled to show the human androgen receptor gene and the nucleic acid sequences in the cDNA clones, human genomic clones, human fibroblast clones, human epididymis  
10 clones, and rat epididymis clones. Human fibroblast clone [1] extended through the stop codon or the C-terminal end of the androgen receptor protein. To isolate and elucidate the sequence of the 5' or N-terminal end of the androgen receptor protein, we used a EcoRI/SstI fragment (EcoRI site was from the linker) from the 5' end  
15 of human epididymis clone [1] as a probe (cDNA probe [A]), to rescreen the human X chromosomal library by standard techniques. By these techniques, human genomic clone [2] was isolated and in turn used as a probe to rescreen a human epididymis library and isolate human epididymis clone [5]. The N-terminal sequence was elucidated  
20 along with the 5' flanking sequence of the androgen receptor protein and gene. Human genomic clones [3], [4] and [5] for the sequence 3' of human genomic clone [1] were obtained using cDNA probes B [a Hind III/EcoRI fragment] and C [an EcoRI fragment], by screening and isolating by standard techniques.

25 Two rat clones, rat epididymis clones [1] and [2], were isolated from a rat epididymis cDNA library using as probes the complete human epididymis clone [1] and a EcoRI/PstI fragment, cDNA probe [D], respectively. These rat clones contained the entire

sequence of the human androgen receptor.

The complete double-stranded sequence encoding the human androgen receptor protein was determined and the deduced amino acid sequence was compared with the sequence of the human androgen receptor protein.

- 17 -

in Figure 4. The cDNA sequence and the amino acid sequence for the rat androgen receptor protein is set forth in Figure 5.

Recombinant DNA clones human fibroblast clone [1] isolated from human foreskin fibroblast cDNA gt11 expression library, human  
5 epididymis clones [1] and [5] isolated from human epididymis cDNA  
gt11 expression library were deposited in the American Type Culture  
Collection with accession numbers ATCC # 40439, ATCC # 40442 and  
ATCC # 40440 respectively. Human genomic clones [1], [2], [3], [4]  
and [5] which were isolated from human X chromosome lambda Charon 35  
10 library available as ATCC # 57750 have been deposited with the  
American Type Culture Collection with accession numbers  
ATCC # 40441, ATCC # 40443, ATCC # 40444, ATCC # 40445 and  
ATCC # 40446 respectively.

A wide variety of host=cloning vehicle combinations may be  
15 usefully employed in cloning the double stranded DNA disclosed  
herein. For example, useful cloning vehicles may include  
chromosomal, non-chromosomal and synthetic DNA sequences such as  
various known bacterial plasmids and wider host range plasmids such  
as pCMV and vectors derived from combinations of plasmids and phage  
20 DNA such as plasmids which have been modified to employ phage DNA  
expression control sequences. Useful hosts may include bacterial  
hosts, yeasts and other fungi, animal or plant hosts, such as  
Chinese Hamster Ovary cells (CHO, or monkey kidney cells (COS M6),  
and other hosts. The particular selection of host-cloning vehicle  
25 combinations may be made by those of skill in the art after due  
consideration of factors such as the source of the DNA- i.e. genomic  
or cDNA.

Cloning vehicles for use in carrying out the present invention

preferred that cloning vehicles further comprise an origin of

- 18 -

replication , as well as sequences which regulate and/or enhance expression levels, depending on the host cell selected.

Techniques for transforming hosts and expressing foreign cloned in them are well known in the art (See, for example, Maniatis et al., *infra*). Cloning vehicles used for expressing foreign genes in bacterial hosts will generally contain a selectable marker, such as a gene for antibiotic resistance, and a promoter which functions in the host cell.

Eukaryotic microorganisms, such as the yeast *Saccharomyces cerevisiae*, may also be used as host cells. Cloning vehicles will generally comprise a selectable marker, such as the nutritional marker TRP, which allows selection in a host strain carrying a *trp1* mutation. To facilitate purification of an androgen receptor protein produced in a yeast transformant, a yeast gene encoding a secreted protein may be joined to the sequence encoding androgen receptor protein.

Higher eukaryotic cells can also serve as host cells in carrying out the present invention. Cultured mammalian cells are preferred. Cloning vehicles for use in mammalian cells will comprise a promoter capable of directing the transcription of a foreign gene introduced into a mammalian cell. Also contained in the expression vector is a polyadenylation signal, located downstream of the insertion site. The polyadenylation signal can be that of the cloned androgen receptor gene, or may be derived from a heterologous gene.

A selectable marker, such as a gene that confers a selectable phenotype, is generally introduced into the cells along with the gene of interest. Preferred selectable markers include genes that

separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid.

The copy marker of the integrated gene sequence can be

removed by a restriction enzyme digestion.

- 19 -

markers. Through selection, expression levels may be substantially increased.

Androgen receptor proteins may be purified from the host cells or cell media according to the present invention using techniques well known to those in the art. Such proteins may be utilized to produce monoclonal or polyclonal antibodies according to the techniques described below.

The techniques of this invention offer considerable advances over existing technology for measurement of androgen receptor. Utilizing proteins and peptides containing the disclosed sequences monoclonal or polyclonal antibodies can be produced for use as immunochemical reagents in immunodiagnostic assays. For example, radioimmunoassays and ELISA assays can be developed utilizing these reagents which will allow detection and quantification of androgen receptor in the presence of endogenous androgen since such androgen will not interfere with antibody binding to the receptor.

Immunocytochemistry utilizing our reagents enables determination and quantification of the cellular distribution of the androgen receptor in tumor tissues, which are often heterogenous in composition. This assay offers great potential for diagnostic evaluation of prostate cancer to determine responsiveness to androgen withdrawal therapy.

In addition, the antibodies produced using the disclosed amino acid sequences can also be used in processes for the purification of androgen receptor protein produced by the above methods. One such purification process is disclosed in Logeat, F., et al., Biochemistry vol. 24 (1985), pp. 1029-1035, which is incorporated by reference herein.

such use range in length from about 3 to about 958 amino acids in length and are preferably from about 15 to about 30 amino acids in

- 20 -

other steroid receptor proteins and larger peptides may contain multiple antigenic determinants; these properties could result in antibodies with cross-reactivities to other steroid receptor proteins.

5       Peptides can be synthesized from amino acid sequences in the  $\text{NH}_2$ -terminal region, the DNA-binding domain, and the carboxyl-terminal steroid binding domain. Peptide selection will be based on hydropathic plots, selecting hydrophilic regions that are more likely exposed on the receptor surface. For diagnostic  
10       purposes preferred sequences will be selected from the  $\text{NH}_2$ -terminal region where there is the least homology with other steroid receptor proteins.

      Peptides for use as immunogens can be synthesized using techniques available to one of ordinary skill in the art. For  
15       example, peptides corresponding to androgen receptor sequences can be synthesized using tBOC chemistry on a Biosearch Model 9500 peptide synthesizer. Peptide purity is assessed by high pressure liquid chromatography. Peptides can be conjugated to keyhole limpet hemocyanin through cysteine residues using the coupling agent  
20       m-maleimido-benzoyl-N-hydroxysuccinimide ester. One can also prepare resin-bound peptides utilizing the p-(oxymethyl benzamide) handle to attach the C-terminal amino acid to solid-phase resin support.

      Proteins and peptides of this invention can be utilized for the  
25       production of polyclonal or monoclonal antibodies. Methods for production of such antibodies are known to those of ordinary skill in the art and may be performed without undue experimentation. One method for the production of monoclonal antibodies is described in

      the art. Polyclonal antibodies, by way of example, can be produced by the method described below.

- 21 -

Peptide conjugates or resin-bound peptides can be injected into rabbits according to the procedure of Vaitukaitis et al., J Clin Endocrinol Metab, 33, 988-991 (1971) using a standard immunization schedule. Antisera titers can be determined in the ELISA assay.

- 5 For example, one androgen receptor sequence, NH<sub>2</sub>-Asp-His-Val-Leu-Pro-Ile-Asp-Tyr-Tyr-Phe-Pro-Pro-Gln-Lys-Thr in the 5' region upstream from the DNA-binding domain, was used to raise antisera in rabbits. The antisera react selectively at a dilution of 1 to 500 with the androgen receptor both in its
- 10 untransformed 8-10S form and in its 4-5S transformed form. Receptor sedimentation on sucrose gradients increases from 4 to 8-10S in the presence of antiserum at high ionic strength and from 8-10S to 11-12S at low ionic strength sucrose gradients. In the ELISA reaction against the peptide used as immunogen, reactivity was
- 15 detectable at 1 to 25,000 dilution. This antiserum at a dilution of 1 to 3000 was found effective in staining nuclear androgen receptor in rat prostate and other male accessory sex glands (see Figure 6).

- Our invention provides new molecular probes comprising complementary DNA sequences derived from the deduced sequences
- 20 encoding the androgen receptor for diagnostic purposes. Such probes may be used to detect the presence of androgen receptor mRNA in tumor cells. Such probes may also be used for detection of androgen receptor gene defects. Androgen receptor complementary DNA sequences can be used as hybridization probes to detect
- 25 abnormalities in the androgen receptor gene or in its messenger RNA.

Androgen receptor DNA sequences disclosed and complementary RNA sequences can be used to construct probes for use in DNA hybridization assays. An example of one such hybridization assay and methods for its use are described in U.S. Patent No. 4,683,194 to Salki et al., and U.S. Patent No. 4,705,886 to Levenson et al., which are hereby incorporated by

reference. The disclosures of U.S. Patent No. 4,683,194 to Salki et al., U.S. Patent No. 4,683,194 to Salki et al., and U.S. Patent No. 4,705,886 to Levenson et al., which are hereby incorporated by

- 22 -

By example, one method for detecting gene deletion utilizes Southern blotting and hybridization. DNA can be isolated from cultured skin fibroblasts or from leukocytes obtained from blood. DNA is cut with restriction enzymes, electrophoresed on an agarose gel, blotted onto nitrocellulose, and hybridized with  
5 [ <sup>32</sup>P]-labeled androgen receptor DNA (see Maniatis, T. et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, incorporated by reference herein).

10 In addition, small mutations can be detected utilizing methods known to one of ordinary skill in the art, from cultured skin fibroblasts of the affected individual. A cDNA library can be prepared using standard techniques. The androgen receptor clones can be isolated using a [ <sup>32</sup>P]DNA AR probe. The clones AR cDNA can then be sequenced and compared to normal AR cDNA sequences.

15 Alternatively genomic DNA can be isolated from blood leukocytes or cultured skin fibroblasts of the affected individual. The DNA is then subjected to restriction enzyme digestion, electrophoresis and is blotted onto nitrocellulose. Synthetic oligonucleotides can be used to bracket specific exons. Exon sequences are amplified using  
20 the polymerase chain reaction, cloned into M13 and sequenced. The sequences are compared to normal human AR DNA sequences.

Another method of identifying small mutations or deletions takes advantage of the ability of RNase A to cleave regions of single stranded RNA in RNA:DNA hybrids. Genomic DNA isolated from  
25 fibroblasts of affected individuals is hybridized with radioactive RNA probes (Promega Biotec) prepared from wild-type androgen receptor cDNA. Mismatches due to mutations would be cleaved by RNase A and result in altered sized bands relative to wild-type on

Androgen receptor gene locus may be used in prenatal diagnosis and carrier detection of androgen insensitivity. For example, the presence of RFLPs in normal individuals is first established by



- 23 -

X chromosomes). DNA can be isolated using the proteinase K procedure and fragmented using a battery of restriction enzymes. Preferred are those enzymes that contain the dinucleotide sequence CG in their recognition sequence. Southern blots are screened with 5-10 kb androgen receptor genomic fragments which if possible lack repetitive DNA. For those regions containing repetitive elements, total human genomic DNA can be added as competitor in the hybridization reaction. Alternatively, one can subclone selected regions to yield a probe free of repetitive elements.

For example, a human restriction fragment length was determined by cDNA probe (B) and Hind III restriction endonuclease using the Southern blot technique (See Figure 7). The two RFLP alleles detected are a fragment at 6.5 kb (allele) and a fragment at 3.5 kb (allele 2). Major constant fragment bands are seen at approximately 2 and 5 kb with minor constant bands at 0.9 and 7.5 kb. Allele 1 is present in approximately 30% of the X chromosomes of the Caucasian population. Allele 2 is present in approximately 20% of the X chromosomes of the Caucasian population. In Figure 8 Lanes A, B and D, DNA from women who are homozygous for allele 1 is shown. In Figure 8 Lane C, DNA from a woman who is heterozygous for both alleles 1 and 2 is shown. Figure 8 Lane E contains DNA from a man that only possesses allele 2. This RFLP, and others determined by the clones we have isolated, will enable one to monitor the androgen receptor gene in various disease conditions described herein.

An example of using the androgen receptor clones to detect mutations is shown in Figure 8 where five different complete androgen insensitive patients' DNA are digested with EcoRI, electrophoresed on a Southern blot, and probed with cDNA probe B. The patient in lane B lacks a 3kb band indicating that part of the

sequencing by standard methods and comparing the abnormal sequence to the normal sequence described herein.

- 24 -

Other potential uses for oligonucleotide sequences disclosed, for example in construction of therapeutics to block genetic expression, will be obvious to one of ordinary skill in the art.

5

10

15

20

25

- 25 -

What is claimed is:

1. A recombinant DNA molecule comprising a DNA sequence encoding the structural gene for androgen receptor protein.

5

2. The recombinant DNA molecule of Claim 1 wherein the androgen receptor protein is a human androgen receptor protein.

3. A cloning vehicle comprising a genomic DNA molecule which upon expression in a eukaryotic host produces androgen receptor protein.

10

4. The cloning vehicle of Claim 3 wherein the androgen receptor protein is a human androgen receptor protein.

15

5. An androgen receptor protein produced by translation of the DNA sequence encoding androgen receptor protein in a host organism transfected or transformed by the cloning vehicle of Claim 3.

20


6. A human androgen receptor protein produced by translation of the DNA sequence encoding human androgen receptor protein in a host organism transfected or transformed by the cloning vehicle of Claim 4.

25

1/2

FIGURE 1 (Page 1 of 2)

A.	Olig	complement	5'-ACC	TGT	GAG	GCG	TGT	AAG	GTC	TTC	TTC	AAA	AG-3'	(1000)
	hAR		ACA	TGT	GCA	ACG	TGC	AAG	GTC	TTC	TTC	AAA	AG	(840)
	hPR		ACC	TGT	GCG	ACG	TGC	AAG	GTC	TTC	TTT	AAG	AG	(880)
	hMR		ACC	TGT	GCG	ACG	TGC	AAA	GTT	TTC	TTC	AAA	AG	(810)
	hGR		ACT	TGT	GCA	ACG	TGT	AAA	GTT	TTC	TTC	AAA	AG	(810)
	hER		TCC	TGT	GAG	GCG	TGT	AAG	GCC	TTC	TTC	AAG	AG	(910)
	hTJR		ACG	TGT	GAA	GCG	TGC	AAG	GCT	TTC	TTT	AGA	AG	(780)
	hMAR		GCC	TGT	GAG	GCG	TGC	AAG	GCG	TTC	TTC	GCG	CG	(780)





2/2

FIGURE 1 (Page 2 of 2)

		DNA-Binding Domain											


3/12

FIGURE 2 (Page 1 of 2)



4/12


FIGURE 2 (Page 2 of 2)



5/12

FIG. 3

COMPILED CLONE MAP OF THE HUMAN ANDROGEN RECEPTOR



Seq  
Uns





FIGURE 4

440 GAAGAGC  
 450 GluGluG  
 460  
 470 TACGGCT  
 480 TyrGlyLys  
 490  
 500  
 510  
 520  
 530  
 540  
 550  
 560  
 570  
 580  
 590  
 600  
 610  
 620  
 630  
 640  
 650  
 660  
 670  
 680  
 690  
 700  
 710  
 720  
 730  
 740  
 750  
 760  
 770  
 780  
 790  
 800  
 810  
 820  
 830  
 840  
 850  
 860  
 870  
 880  
 890  
 900  
 910  
 920  
 930  
 940  
 950  
 960  
 970  
 980  
 990  
 1000  
 1010  
 1020  
 1030  
 1040  
 1050  
 1060  
 1070  
 1080  
 1090  
 1100  
 1110  
 1120  
 1130  
 1140  
 1150  
 1160  
 1170  
 1180  
 1190  
 1200  
 1210  
 1220  
 1230  
 1240  
 1250  
 1260  
 1270  
 1280  
 1290  
 1300  
 1310  
 1320  
 1330  
 1340  
 1350  
 1360  
 1370  
 1380  
 1390  
 1400  
 1410  
 1420  
 1430  
 1440  
 1450  
 1460  
 1470  
 1480  
 1490  
 1500  
 1510  
 1520  
 1530  
 1540  
 1550  
 1560  
 1570  
 1580  
 1590  
 1600  
 1610  
 1620  
 1630  
 1640  
 1650  
 1660  
 1670  
 1680  
 1690  
 1700  
 1710  
 1720  
 1730  
 1740  
 1750  
 1760  
 1770  
 1780  
 1790  
 1800  
 1810  
 1820  
 1830  
 1840  
 1850  
 1860  
 1870  
 1880  
 1890  
 1900  
 1910  
 1920  
 1930  
 1940  
 1950  
 1960  
 1970  
 1980  
 1990  
 2000  
 2010  
 2020  
 2030  
 2040  
 2050  
 2060  
 2070  
 2080  
 2090  
 2100  
 2110  
 2120  
 2130  
 2140  
 2150  
 2160  
 2170  
 2180  
 2190  
 2200  
 2210  
 2220  
 2230  
 2240  
 2250  
 2260  
 2270  
 2280  
 2290  
 2300  
 2310  
 2320  
 2330  
 2340  
 2350  
 2360  
 2370  
 2380  
 2390  
 2400  
 2410  
 2420  
 2430  
 2440  
 2450  
 2460  
 2470  
 2480  
 2490  
 2500  
 2510  
 2520  
 2530  
 2540  
 2550  
 2560  
 2570  
 2580  
 2590  
 2600  
 2610  
 2620  
 2630  
 2640  
 2650  
 2660  
 2670  
 2680  
 2690  
 2700  
 2710  
 2720  
 2730  
 2740  
 2750  
 2760  
 2770  
 2780  
 2790  
 2800  
 2810  
 2820  
 2830  
 2840  
 2850  
 2860  
 2870  
 2880  
 2890  
 2900  
 2910  
 2920  
 2930  
 2940  
 2950  
 2960  
 2970  
 2980  
 2990  
 3000  
 3010  
 3020  
 3030  
 3040  
 3050  
 3060  
 3070  
 3080  
 3090  
 3100  
 3110  
 3120  
 3130  
 3140  
 3150  
 3160  
 3170  
 3180  
 3190  
 3200  
 3210  
 3220  
 3230  
 3240  
 3250  
 3260  
 3270  
 3280  
 3290  
 3300  
 3310  
 3320  
 3330  
 3340  
 3350  
 3360  
 3370  
 3380  
 3390  
 3400  
 3410  
 3420  
 3430  
 3440  
 3450  
 3460  
 3470  
 3480  
 3490  
 3500  
 3510  
 3520  
 3530  
 3540  
 3550  
 3560  
 3570  
 3580  
 3590  
 3600  
 3610  
 3620  
 3630  
 3640  
 3650  
 3660  
 3670  
 3680  
 3690  
 3700  
 3710  
 3720  
 3730  
 3740  
 3750  
 3760  
 3770  
 3780  
 3790  
 3800  
 3810  
 3820  
 3830  
 3840  
 3850  
 3860  
 3870  
 3880  
 3890  
 3900  
 3910  
 3920  
 3930  
 3940  
 3950  
 3960  
 3970  
 3980  
 3990  
 4000  
 4010  
 4020  
 4030  
 4040  
 4050  
 4060  
 4070  
 4080  
 4090  
 4100  
 4110  
 4120  
 4130  
 4140  
 4150  
 4160  
 4170  
 4180  
 4190  
 4200  
 4210  
 4220  
 4230  
 4240  
 4250  
 4260  
 4270  
 4280  
 4290  
 4300  
 4310  
 4320  
 4330  
 4340  
 4350  
 4360  
 4370  
 4380  
 4390  
 4400  
 4410  
 4420  
 4430  
 4440  
 4450  
 4460  
 4470  
 4480  
 4490  
 4500  
 4510  
 4520  
 4530  
 4540  
 4550  
 4560  
 4570  
 4580  
 4590  
 4600  
 4610  
 4620  
 4630  
 4640  
 4650  
 4660  
 4670  
 4680  
 4690  
 4700  
 4710  
 4720  
 4730  
 4740  
 4750  
 4760  
 4770  
 4780  
 4790  
 4800  
 4810  
 4820  
 4830  
 4840  
 4850  
 4860  
 4870  
 4880  
 4890  
 4900  
 4910  
 4920  
 4930  
 4940  
 4950  
 4960  
 4970  
 4980  
 4990  
 5000  
 5010  
 5020  
 5030  
 5040  
 5050  
 5060  
 5070  
 5080  
 5090  
 5100  
 5110  
 5120  
 5130  
 5140  
 5150  
 5160  
 5170  
 5180  
 5190  
 5200  
 5210  
 5220  
 5230  
 5240  
 5250  
 5260  
 5270  
 5280  
 5290  
 5300  
 5310  
 5320  
 5330  
 5340  
 5350  
 5360  
 5370  
 5380  
 5390  
 5400  
 5410  
 5420  
 5430  
 5440  
 5450  
 5460  
 5470  
 5480  
 5490  
 5500  
 5510  
 5520  
 5530  
 5540  
 5550  
 5560  
 5570  
 5580  
 5590  
 5600  
 5610  
 5620  
 5630  
 5640  
 5650  
 5660  
 5670  
 5680  
 5690  
 5700  
 5710  
 5720  
 5730  
 5740  
 5750  
 5760  
 5770  
 5780  
 5790  
 5800  
 5810  
 5820  
 5830  
 5840  
 5850  
 5860  
 5870  
 5880  
 5890  
 5900  
 5910  
 5920  
 5930  
 5940  
 5950  
 5960  
 5970  
 5980  
 5990  
 6000  
 6010  
 6020  
 6030  
 6040  
 6050  
 6060  
 6070  
 6080  
 6090  
 6100  
 6110  
 6120  
 6130  
 6140  
 6150  
 6160  
 6170  
 6180  
 6190  
 6200  
 6210  
 6220  
 6230  
 6240  
 6250  
 6260  
 6270  
 6280  
 6290  
 6300  
 6310  
 6320  
 6330  
 6340  
 6350  
 6360  
 6370  
 6380  
 6390  
 6400  
 6410  
 6420  
 6430  
 6440  
 6450  
 6460  
 6470  
 6480  
 6490  
 6500  
 6510  
 6520  
 6530  
 6540  
 6550  
 6560  
 6570  
 6580  
 6590  
 6600  
 6610  
 6620  
 6630  
 6640  
 6650  
 6660  
 6670  
 6680  
 6690  
 6700  
 6710  
 6720  
 6730  
 6740  
 6750  
 6760  
 6770  
 6780  
 6790  
 6800  
 6810  
 6820  
 6830  
 6840  
 6850  
 6860  
 6870  
 6880  
 6890  
 6900  
 6910  
 6920  
 6930  
 6940  
 6950  
 6960  
 6970  
 6980  
 6990  
 7000  
 7010  
 7020  
 7030  
 7040  
 7050  
 7060  
 7070  
 7080  
 7090  
 7100  
 7110  
 7120  
 7130  
 7140  
 7150  
 7160  
 7170  
 7180  
 7190  
 7200  
 7210  
 7220  
 7230  
 7240  
 7250  
 7260  
 7270  
 7280  
 7290  
 7300  
 7310  
 7320  
 7330  
 7340  
 7350  
 7360  
 7370  
 7380  
 7390  
 7400  
 7410  
 7420  
 7430  
 7440  
 7450  
 7460  
 7470  
 7480  
 7490  
 7500  
 7510  
 7520  
 7530  
 7540  
 7550  
 7560  
 7570  
 7580  
 7590  
 7600  
 7610  
 7620  
 7630  
 7640  
 7650  
 7660  
 7670  
 7680  
 7690  
 7700  
 7710  
 7720  
 7730  
 7740  
 7750  
 7760  
 7770  
 7780  
 7790  
 7800  
 7810  
 7820  
 7830  
 7840  
 7850  
 7860  
 7870  
 7880  
 7890  
 7900  
 7910  
 7920  
 7930  
 7940  
 7950  
 7960  
 7970  
 7980  
 7990  
 8000  
 8010  
 8020  
 8030  
 8040  
 8050  
 8060  
 8070  
 8080  
 8090  
 8100  
 8110  
 8120  
 8130  
 8140  
 8150  
 8160  
 8170  
 8180  
 8190  
 8200  
 8210  
 8220  
 8230  
 8240  
 8250  
 8260  
 8270  
 8280  
 8290  
 8300  
 8310  
 8320  
 8330  
 8340  
 8350  
 8360  
 8370  
 8380  
 8390  
 8400  
 8410  
 8420  
 8430  
 8440  
 8450  
 8460  
 8470  
 8480  
 8490  
 8500  
 8510  
 8520  
 8530  
 8540  
 8550  
 8560  
 8570  
 8580  
 8590  
 8600  
 8610  
 8620  
 8630  
 8640  
 8650  
 8660  
 8670  
 8680  
 8690  
 8700  
 8710  
 8720  
 8730  
 8740  
 8750  
 8760  
 8770  
 8780  
 8790  
 8800  
 8810  
 8820  
 8830  
 8840  
 8850  
 8860  
 8870  
 8880  
 8890  
 8900  
 8910  
 8920  
 8930  
 8940  
 8950  
 8960  
 8970  
 8980  
 8990  
 9000  
 9010  
 9020  
 9030  
 9040  
 9050  
 9060  
 9070  
 9080  
 9090  
 9100  
 9110  
 9120  
 9130  
 9140  
 9150  
 9160  
 9170  
 9180  
 9190  
 9200  
 9210  
 9220  
 9230  
 9240  
 9250  
 9260  
 9270  
 9280  
 9290  
 9300  
 9310  
 9320  
 9330  
 9340  
 9350  
 9360  
 9370  
 9380  
 9390  
 9400  
 9410  
 9420  
 9430  
 9440  
 9450  
 9460  
 9470  
 9480  
 9490  
 9500  
 9510  
 9520  
 9530  
 9540  
 9550  
 9560  
 9570  
 9580  
 9590  
 9600  
 9610  
 9620  
 9630  
 9640  
 9650  
 9660  
 9670  
 9680  
 9690  
 9700  
 9710  
 9720  
 9730  
 9740  
 9750  
 9760  
 9770  
 9780  
 9790  
 9800  
 9810  
 9820  
 9830  
 9840  
 9850  
 9860  
 9870  
 9880  
 9890  
 9900  
 9910  
 9920  
 9930  
 9940  
 9950  
 9960  
 9970  
 9980  
 9990  
 10000  
 10010  
 10020  
 10030  
 10040  
 10050  
 10060  
 10070  
 10080  
 10090  
 10100  
 10110  
 10120  
 10130  
 10140  
 10150  
 10160  
 10170  
 10180  
 10190  
 10200  
 10210  
 10220  
 10230  
 10240  
 10250  
 10260  
 10270  
 10280  
 10290  
 10300  
 10310  
 10320  
 10330  
 10340  
 10350  
 10360  
 10370  
 10380  
 10390  
 10400  
 10410  
 10420  
 10430  
 10440  
 10450  
 10460  
 10470  
 10480  
 10490  
 10500  
 10510  
 10520  
 10530  
 10540  
 10550  
 10560  
 10570  
 10580  
 10590  
 10600  
 10610  
 10620  
 10630  
 10640  
 10650  
 10660  
 10670  
 10680  
 10690  
 10700  
 10710  
 10720  
 10730  
 10740  
 10750  
 10760  
 10770  
 10780  
 10790  
 10800  
 10810  
 10820  
 10830  
 10840  
 10850  
 10860  
 10870  
 10880  
 10890  
 10900  
 10910  
 10920  
 10930  
 10940  
 10950  
 10960  
 10970  
 10980  
 10990  
 11000  
 11010  
 11020  
 11030  
 11040  
 11050  
 11060  
 11070  
 11080  
 11090  
 11100  
 11110  
 11120  
 11130  
 11140  
 11150  
 11160  
 11170  
 11180  
 11190  
 11200  
 11210  
 11220  
 11230  
 11240  
 11250  
 11260  
 11270  
 11280  
 11290  
 11300  
 11310  
 11320  
 11330  
 11340  
 11350  
 11360  
 11370  
 11380  
 11390  
 11400  
 11410  
 11420  
 11430  
 11440  
 11450  
 11460  
 11470  
 11480  
 11490  
 11500  
 11510  
 11520  
 11530  
 11540  
 11550  
 11560  
 11570  
 11580  
 11590  
 11600  
 11610  
 11620  
 11630  
 11640  
 11650  
 11660  
 11670  
 11680  
 11690  
 11700  
 11710  
 11720  
 11730  
 11740  
 11750  
 11760  
 11770  
 11780  
 11790  
 11800  
 11810  
 11820  
 11830  
 11840  
 11850  
 11860  
 11870  
 11880  
 11890  
 11900  
 11910  
 11920  
 11930  
 11940  
 11950  
 11960  
 11970  
 11980  
 11990  
 12000  
 12010  
 12020  
 12030  
 12040  
 12050  
 12060  
 12070  
 12080  
 12090  
 12100  
 12110  
 12120  
 12130  
 12140  
 12150  
 12160  
 12170  
 12180  
 12190  
 12200  
 12210  
 12220  
 12230  
 12240  
 12250  
 12260  
 12270  
 12280  
 12290  
 12300  
 12310  
 12320  
 12330  
 12340  
 12350  
 12360  
 12370  
 12380  
 12390  
 12400  
 12410  
 12420  
 12430  
 12440  
 12450  
 12460  
 12470  
 12480  
 12490  
 12500  
 12510  
 12520  
 12530  
 12540  
 12550  
 12560  
 12570  
 12580  
 12590  
 12600  
 12610  
 12620  
 12630  
 12640  
 12650  
 12660  
 12670  
 12680  
 12690  
 12700  
 12710  
 12720  
 12730  
 12740  
 12750  
 12760  
 12770  
 12780  
 12790  
 12800  
 12810  
 12820  
 12830  
 12840  
 12850  
 12860  
 12870  
 12880  
 12890  
 12900  
 12910  
 12920  
 12930  
 12940  
 12950  
 12960  
 12970  
 12980  
 12990  
 13000  
 13010  
 13020  
 13030  
 13040  
 13050  
 13060  
 13070  
 13080  
 13090  
 13100  
 13110  
 13120  
 13130  
 13140  
 13150  
 13160  
 13170  
 13180  
 13190  
 13200  
 13210  
 13220  
 13230  
 13240  
 13250  
 13260  
 13270  
 13280  
 13290  
 13300  
 13310  
 13320  
 13330  
 13340  
 13350  
 13360  
 13370  
 13380  
 13390  
 13400  
 13410  
 13420  
 13430  
 13440  
 13450  
 13460  
 13470  
 13480  
 13490  
 13500  
 13510  
 13520  
 13530  
 13540  
 13550  
 13560  
 13570  
 13580  
 13590  
 13600  
 13610  
 13620  
 136

8/12

**FIGURE 4**

Page 3 of 3

3340 GAAAGCAATT  
 3341  
 3342  
 3343  
 3344 GAGCTGTGTCA  
 3345  
 3346 CCCATTGTGGT  
 3347  
 3348 AACCGTTTACTT  
 3349  
 3350  
 3351  
 3352  
 3353  
 3354  
 3355  
 3356  
 3357  
 3358  
 3359  
 3360  
 3361  
 3362  
 3363  
 3364  
 3365  
 3366  
 3367  
 3368  
 3369  
 3370  
 3371  
 3372  
 3373  
 3374  
 3375  
 3376  
 3377  
 3378  
 3379  
 3380  
 3381  
 3382  
 3383  
 3384  
 3385  
 3386  
 3387  
 3388  
 3389  
 3390  
 3391  
 3392  
 3393  
 3394  
 3395  
 3396  
 3397  
 3398  
 3399  
 3400  
 3401  
 3402  
 3403  
 3404  
 3405  
 3406  
 3407  
 3408  
 3409  
 3410  
 3411  
 3412  
 3413  
 3414  
 3415  
 3416  
 3417  
 3418  
 3419  
 3420  
 3421  
 3422  
 3423  
 3424  
 3425  
 3426  
 3427  
 3428  
 3429  
 3430  
 3431  
 3432  
 3433  
 3434  
 3435  
 3436  
 3437  
 3438  
 3439  
 3440  
 3441  
 3442  
 3443  
 3444  
 3445  
 3446  
 3447  
 3448  
 3449  
 3450  
 3451  
 3452  
 3453  
 3454  
 3455  
 3456  
 3457  
 3458  
 3459  
 3460  
 3461  
 3462  
 3463  
 3464  
 3465  
 3466  
 3467  
 3468  
 3469  
 3470  
 3471  
 3472  
 3473  
 3474  
 3475  
 3476  
 3477  
 3478  
 3479  
 3480  
 3481  
 3482  
 3483  
 3484  
 3485  
 3486  
 3487  
 3488  
 3489  
 3490  
 3491  
 3492  
 3493  
 3494  
 3495  
 3496  
 3497  
 3498  
 3499  
 3500  
 3501  
 3502  
 3503  
 3504  
 3505  
 3506  
 3507  
 3508  
 3509  
 3510  
 3511  
 3512  
 3513  
 3514  
 3515  
 3516  
 3517  
 3518  
 3519  
 3520  
 3521  
 3522  
 3523  
 3524  
 3525  
 3526  
 3527  
 3528  
 3529  
 3530  
 3531  
 3532  
 3533  
 3534  
 3535  
 3536  
 3537  
 3538  
 3539  
 3540  
 3541  
 3542  
 3543  
 3544  
 3545  
 3546  
 3547  
 3548  
 3549  
 3550  
 3551  
 3552  
 3553  
 3554  
 3555  
 3556  
 3557  
 3558  
 3559  
 3560  
 3561  
 3562  
 3563  
 3564  
 3565  
 3566  
 3567  
 3568  
 3569  
 3570  
 3571  
 3572  
 3573  
 3574  
 3575  
 3576  
 3577  
 3578  
 3579  
 3580  
 3581  
 3582  
 3583  
 3584  
 3585  
 3586  
 3587  
 3588  
 3589  
 3590  
 3591  
 3592  
 3593  
 3594  
 3595  
 3596  
 3597  
 3598  
 3599  
 3600  
 3601  
 3602  
 3603  
 3604  
 3605  
 3606  
 3607  
 3608  
 3609  
 3610  
 3611  
 3612  
 3613  
 3614  
 3615  
 3616  
 3617  
 3618  
 3619  
 3620  
 3621  
 3622  
 3623  
 3624  
 3625  
 3626  
 3627  
 3628  
 3629  
 3630  
 3631  
 3632  
 3633  
 3634  
 3635  
 3636  
 3637  
 3638  
 3639  
 3640  
 3641  
 3642  
 3643  
 3644  
 3645  
 3646  
 3647  
 3648  
 3649  
 3650  
 3651  
 3652  
 3653  
 3654  
 3655  
 3656  
 3657  
 3658  
 3659  
 3660  
 3661  
 3662  
 3663  
 3664  
 3665  
 3666  
 3667  
 3668  
 3669  
 3670  
 3671  
 3672  
 3673  
 3674  
 3675  
 3676  
 3677  
 3678  
 3679  
 3680  
 3681  
 3682  
 3683  
 3684  
 3685  
 3686  
 3687  
 3688  
 3689  
 3690  
 3691  
 3692  
 3693  
 3694  
 3695  
 3696  
 3697  
 3698  
 3699  
 3700  
 3701  
 3702  
 3703  
 3704  
 3705  
 3706  
 3707  
 3708  
 3709  
 3710  
 3711  
 3712  
 3713  
 3714  
 3715  
 3716  
 3717  
 3718  
 3719  
 3720  
 3721  
 3722  
 3723  
 3724  
 3725  
 3726  
 3727  
 3728  
 3729  
 3730  
 3731  
 3732  
 3733  
 3734  
 3735  
 3736  
 3737  
 3738  
 3739  
 3740  
 3741  
 3742  
 3743  
 3744  
 3745  
 3746  
 3747  
 3748  
 3749  
 3750  
 3751  
 3752  
 3753  
 3754  
 3755  
 3756  
 3757  
 3758  
 3759  
 3760  
 3761  
 3762  
 3763  
 3764  
 3765  
 3766  
 3767  
 3768  
 3769  
 3770  
 3771  
 3772  
 3773  
 3774  
 3775  
 3776  
 3777  
 3778  
 3779  
 3780  
 3781  
 3782  
 3783  
 3784  
 3785  
 3786  
 3787  
 3788  
 3789  
 3790  
 3791  
 3




FIGURE 5 (Page 2 of 3)

350 ACAGAGGCTACACGCTTTCGGCTCGCTGTCGCGGCGCCGCCACCCCGCCCTACCCATCCACACGCGCCGCATCAAGCTGGAGAACCCGTG 2160  
 360 rGlnAsnArgAspTyrTyrAsnPheProLeuAlaLeuSerGlyProProHisProProProHisAlaArgIleLysLeuGluAsnProSer  
 370 380  
 390 400  
 410 420  
 430 440  
 450 460  
 470 480  
 490 500  
 510 520  
 530 540  
 550 560  
 570 580  
 590 600  
 610 620  
 630 640  
 650 660  
 670 680  
 690 700  
 710 720  
 730 740  
 750 760  
 770 780  
 790 800  
 810 820  
 830 840  
 850 860  
 870 880  
 890 900  
 910 920  
 930 940  
 950 960  
 970 980  
 990 1000  
 1010 1020  
 1030 1040  
 1050 1060  
 1070 1080  
 1090 1100  
 1110 1120  
 1130 1140  
 1150 1160  
 1170 1180  
 1190 1200  
 1210 1220  
 1230 1240  
 1250 1260  
 1270 1280  
 1290 1300  
 1310 1320  
 1330 1340  
 1350 1360  
 1370 1380  
 1390 1400  
 1410 1420  
 1430 1440  
 1450 1460  
 1470 1480  
 1490 1500  
 1510 1520  
 1530 1540  
 1550 1560  
 1570 1580  
 1590 1600  
 1610 1620  
 1630 1640  
 1650 1660  
 1670 1680  
 1690 1700  
 1710 1720  
 1730 1740  
 1750 1760  
 1770 1780  
 1790 1800  
 1810 1820  
 1830 1840  
 1850 1860  
 1870 1880  
 1890 1900  
 1910 1920  
 1930 1940  
 1950 1960  
 1970 1980  
 1990 2000  
 2010 2020  
 2030 2040  
 2050 2060  
 2070 2080  
 2090 2100  
 2110 2120  
 2130 2140  
 2150 2160  
 2170 2180  
 2190 2200  
 2210 2220  
 2230 2240  
 2250 2260  
 2270 2280  
 2290 2300  
 2310 2320  
 2330 2340  
 2350 2360  
 2370 2380  
 2390 2400  
 2410 2420  
 2430 2440  
 2450 2460  
 2470 2480  
 2490 2500  
 2510 2520  
 2530 2540  
 2550 2560  
 2570 2580  
 2590 2600  
 2610 2620  
 2630 2640  
 2650 2660  
 2670 2680  
 2690 2700  
 2710 2720  
 2730 2740  
 2750 2760  
 2770 2780  
 2790 2800  
 2810 2820  
 2830 2840  
 2850 2860  
 2870 2880  
 2890 2900  
 2910 2920  
 2930 2940  
 2950 2960  
 2970 2980  
 2990 3000  
 3010 3020  
 3030 3040  
 3050 3060  
 3070 3080  
 3090 3100  
 3110 3120  
 3130 3140  
 3150 3160  
 3170 3180  
 3190 3200  
 3210 3220  
 3230 3240  
 3250 3260  
 3270 3280  
 3290 3300  
 3310 3320  
 3330 3340  
 3350 3360  
 3370 3380  
 3390 3400  
 3410 3420  
 3430 3440  
 3450 3460  
 3470 3480  
 3490 3500  
 3510 3520  
 3530 3540  
 3550 3560  
 3570 3580  
 3590 3600  
 3610 3620  
 3630 3640  
 3650 3660  
 3670 3680  
 3690 3700  
 3710 3720  
 3730 3740  
 3750 3760  
 3770 3780  
 3790 3800  
 3810 3820  
 3830 3840  
 3850 3860  
 3870 3880  
 3890 3900  
 3910 3920  
 3930 3940  
 3950 3960  
 3970 3980  
 3990 4000  
 4010 4020  
 4030 4040  
 4050 4060  
 4070 4080  
 4090 4100  
 4110 4120  
 4130 4140  
 4150 4160  
 4170 4180  
 4190 4200  
 4210 4220  
 4230 4240  
 4250 4260  
 4270 4280  
 4290 4300  
 4310 4320  
 4330 4340  
 4350 4360  
 4370 4380  
 4390 4400  
 4410 4420  
 4430 4440  
 4450 4460  
 4470 4480  
 4490 4500  
 4510 4520  
 4530 4540  
 4550 4560  
 4570 4580  
 4590 4600  
 4610 4620  
 4630 4640  
 4650 4660  
 4670 4680  
 4690 4700  
 4710 4720  
 4730 4740  
 4750 4760  
 4770 4780  
 4790 4800  
 4810 4820  
 4830 4840  
 4850 4860  
 4870 4880  
 4890 4900  
 4910 4920  
 4930 4940  
 4950 4960  
 4970 4980  
 4990 5000  
 5010 5020  
 5030 5040  
 5050 5060  
 5070 5080  
 5090 5100  
 5110 5120  
 5130 5140  
 5150 5160  
 5170 5180  
 5190 5200  
 5210 5220  
 5230 5240  
 5250 5260  
 5270 5280  
 5290 5300  
 5310 5320  
 5330 5340  
 5350 5360  
 5370 5380  
 5390 5400  
 5410 5420  
 5430 5440  
 5450 5460  
 5470 5480  
 5490 5500  
 5510 5520  
 5530 5540  
 5550 5560  
 5570 5580  
 5590 5600  
 5610 5620  
 5630 5640  
 5650 5660  
 5670 5680  
 5690 5700  
 5710 5720  
 5730 5740  
 5750 5760  
 5770 5780  
 5790 5800  
 5810 5820  
 5830 5840  
 5850 5860  
 5870 5880  
 5890 5900  
 5910 5920  
 5930 5940  
 5950 5960  
 5970 5980  
 5990 6000  
 6010 6020  
 6030 6040  
 6050 6060  
 6070 6080  
 6090 6100  
 6110 6120  
 6130 6140  
 6150 6160  
 6170 6180  
 6190 6200  
 6210 6220  
 6230 6240  
 6250 6260  
 6270 6280  
 6290 6300  
 6310 6320  
 6330 6340  
 6350 6360  
 6370 6380  
 6390 6400  
 6410 6420  
 6430 6440  
 6450 6460  
 6470 6480  
 6490 6500  
 6510 6520  
 6530 6540  
 6550 6560  
 6570 6580  
 6590 6600  
 6610 6620  
 6630 6640  
 6650 6660  
 6670 6680  
 6690 6700  
 6710 6720  
 6730 6740  
 6750 6760  
 6770 6780  
 6790 6800  
 6810 6820  
 6830 6840  
 6850 6860  
 6870 6880  
 6890 6900  
 6910 6920  
 6930 6940  
 6950 6960  
 6970 6980  
 6990 7000  
 7010 7020  
 7030 7040  
 7050 7060  
 7070 7080  
 7090 7100  
 7110 7120  
 7130 7140  
 7150 7160  
 7170 7180  
 7190 7200  
 7210 7220  
 7230 7240  
 7250 7260  
 7270 7280  
 7290 7300  
 7310 7320  
 7330 7340  
 7350 7360  
 7370 7380  
 7390 7400  
 7410 7420  
 7430 7440  
 7450 7460  
 7470 7480  
 7490 7500  
 7510 7520  
 7530 7540  
 7550 7560  
 7570 7580  
 7590 7600  
 7610 7620  
 7630 7640  
 7650 7660  
 7670 7680  
 7690 7700  
 7710 7720  
 7730 7740  
 7750 7760  
 7770 7780  
 7790 7800  
 7810 7820  
 7830 7840  
 7850 7860  
 7870 7880  
 7890 7900  
 7910 7920  
 7930 7940  
 7950 7960  
 7970 7980  
 7990 8000  
 8010 8020  
 8030 8040  
 8050 8060  
 8070 8080  
 8090 8100  
 8110 8120  
 8130 8140  
 8150 8160  
 8170 8180  
 8190 8200  
 8210 8220  
 8230 8240  
 8250 8260  
 8270 8280  
 8290 8300  
 8310 8320  
 8330 8340  
 8350 8360  
 8370 8380  
 8390 8400  
 8410 8420  
 8430 8440  
 8450 8460  
 8470 8480  
 8490 8500  
 8510 8520  
 8530 8540  
 8550 8560  
 8570 8580  
 8590 8600  
 8610 8620  
 8630 8640  
 8650 8660  
 8670 8680  
 8690 8700  
 8710 8720  
 8730 8740  
 8750 8760  
 8770 8780  
 8790 8800  
 8810 8820  
 8830 8840  
 8850 8860  
 8870 8880  
 8890 8900  
 8910 8920  
 8930 8940  
 8950 8960  
 8970 8980  
 8990 9000  
 9010 9020  
 9030 9040  
 9050 9060  
 9070 9080  
 9090 9100  
 9110 9120  
 9130 9140  
 9150 9160  
 9170 9180  
 9190 9200  
 9210 9220  
 9230 9240  
 9250 9260  
 9270 9280  
 9290 9300  
 9310 9320  
 9330 9340  
 9350 9360  
 9370 9380  
 9390 9400  
 9410 9420  
 9430 9440  
 9450 9460  
 9470 9480  
 9490 9500  
 9510 9520  
 9530 9540  
 9550 9560  
 9570 9580  
 9590 9600  
 9610 9620  
 9630 9640  
 9650 9660  
 9670 9680  
 9690 9700  
 9710 9720  
 9730 9740  
 9750 9760  
 9770 9780  
 9790 9800  
 9810 9820  
 9830 9840  
 9850 9860  
 9870 9880  
 9890 9900  
 9910 9920  
 9930 9940  
 9950 9960  
 9970 9980  
 9990 10000



FIGURE 6



SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/01548

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4): C07K 15/00, C07H 17/02, C12N 15/00 U.S. CL.: 530/387; 536/27; 435/320														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border: 1px solid black; text-align: left; padding: 5px;">Classification System</th> <th style="border: 1px solid black; text-align: left; padding: 5px;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 10px; vertical-align: top;">U.S.</td> <td style="border: 1px solid black; padding: 10px;">530/387 536/27 435/320, 70, 325, 172.3</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div> <p style="margin-top: 10px;">Chem. Abstracts database, Genbank sequence search Keywords: human androgen receptor, DNA, cDNA, vector, clon?</p>			Classification System	Classification Symbols	U.S.	530/387 536/27 435/320, 70, 325, 172.3								
Classification System	Classification Symbols													
U.S.	530/387 536/27 435/320, 70, 325, 172.3													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; border: 1px solid black; text-align: left; padding: 5px;">Category <sup>*</sup></th> <th style="border: 1px solid black; text-align: left; padding: 5px;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="border: 1px solid black; text-align: left; padding: 5px;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">X, P</td> <td style="border: 1px solid black; padding: 5px;"> <u>Biochemical and Biophysical Research Communications</u>, Volume 153 Issued 31 May 1988, TRAPMAN "Cloning Structure and expression of a cDNA encoding the human androgen receptor" See pages 241-248, especially figures 2 and 3.         </td> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">1-6</td> </tr> <tr> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">X, P Y, P</td> <td style="border: 1px solid black; padding: 5px;"> <u>Chemical Abstracts</u>, Volume 109(23) Issued 05 December 1988            GOVINDAN "Cloning of the human androgen receptor cDNA" See page 205.         </td> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">1-4 5-6</td> </tr> <tr> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">X</td> <td style="border: 1px solid black; padding: 5px;"> <u>Science</u>, Volume 240, Issued 15 April 1988 LUBAHN "Cloning of Human Androgen receptor complementary DNA and localization to the X Chromosome". See pages 327-330.         </td> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">1-6</td> </tr> </tbody> </table>			Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X, P	<u>Biochemical and Biophysical Research Communications</u> , Volume 153 Issued 31 May 1988, TRAPMAN "Cloning Structure and expression of a cDNA encoding the human androgen receptor" See pages 241-248, especially figures 2 and 3.	1-6	X, P Y, P	<u>Chemical Abstracts</u> , Volume 109(23) Issued 05 December 1988 GOVINDAN "Cloning of the human androgen receptor cDNA" See page 205.	1-4 5-6	X	<u>Science</u> , Volume 240, Issued 15 April 1988 LUBAHN "Cloning of Human Androgen receptor complementary DNA and localization to the X Chromosome". See pages 327-330.	1-6
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X, P	<u>Biochemical and Biophysical Research Communications</u> , Volume 153 Issued 31 May 1988, TRAPMAN "Cloning Structure and expression of a cDNA encoding the human androgen receptor" See pages 241-248, especially figures 2 and 3.	1-6												
X, P Y, P	<u>Chemical Abstracts</u> , Volume 109(23) Issued 05 December 1988 GOVINDAN "Cloning of the human androgen receptor cDNA" See page 205.	1-4 5-6												
X	<u>Science</u> , Volume 240, Issued 15 April 1988 LUBAHN "Cloning of Human Androgen receptor complementary DNA and localization to the X Chromosome". See pages 327-330.	1-6												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention</p> </div> </div>														

## CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

12 July 1989

12 SEP 1989

INTERNATIONAL SEARCHING AUTHORITY  
 PCT/US/89/01548



III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	<u>Science</u> , Volume 240, Issued 15 April 1988 CHANG "Molecular Cloning of human and rat complementary DNA encoding androgen receptors" See pages 324-326.	1-6
Y	<u>Nature</u> , Volume 324, Issued 18/25 December 1986 WEIMBERGER "The c-erb-A gene encodes a thyroid hormone receptor" See pages 641-646. especially first paragraph page 641.	1-4
Y	<u>Nature</u> , Volume 320 Issued 13 March 1986 GREEN "Human Oestrogen receptor cDNA: sequence, expression and homology to v-erb-A.	1-4

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_, because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:

2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

Group I, claims 1-4, drawn to a recombinant DNA molecule and a cloning vector.

Group II, claims 5 & 6 drawn to an adrogen receptor protein.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. Telephone Practice

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.